Advertisement
The symposium, which will take place on April 23 at the Convention Centerof Sheraton Grande Walkerhill Seoul Hotel in Seoul, Korea, includes:
"Recent data has highlighted the need for a safer alternative todrug-eluting stents," said Seung-Jung Park. "The data we have seen from boththe TRIAS HR Pilot study and the registries underline Genous' superior safetyprofile with regards to late stage thrombosis."
Advertisement
Unlike drug-eluting stents, Genous, which is coated with an antibody,captures a patient's endothelial progenitor cells (EPCs) to accelerate thenatural healing process. EPCs circulate in the bloodstream and are involvedin the repair of blood vessels. When attracted to the surface of Genous, EPCsrapidly form an endothelial layer over the stent that provides protectionagainst thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medicaldevices for the treatment of vascular diseases. The company's productportfolio includes the Genous Bio-engineered R stent, an antibody-coateddevice that is the first-ever stent to capture a patient's endothelialprogenitor cells (EPCs) to accelerate the natural healing process followingplacement. Other products are stents, balloons and guiding catheters marketedunder the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), AvitaHP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and hasoperations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; andShenzhen, China. OrbusNeich, which has provided cardiology devices tophysicians through its predecessor companies since 1979, today suppliesproducts to interventional cardiologists in more than 60 countries. For moreinformation, visit www.OrbusNeich.com .-- "Opening Address" by Seung-Jung Park, the symposium's chairperson, from 12:30 p.m.-12:35 p.m. -- "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael Kutryk from 12:35 p.m.-12:50 p.m. -- "TRIAS HR Pilot Study Long Term Follow-up" by Robbert de Winter of the Academic Medical Center, Amsterdam, from 12:50 p.m.-1:05 p.m. -- "HEALING AMI" by Harry Suryapranata from 1:05 p.m.-1:20 p.m. -- "Q&A Followed by Closing Remarks" by Seung-Jung Park from 1:20 p.m.-1:30 p.m.
SOURCE OrbusNeich
